North America
The data, while limited, indicate that the firm's blood-only assay may be able to match the performance of existing commercial tissue-informed competitors.
In Brief This Week:Â Cleveland Diagnostics, Genprex, Viome
News items for the week of May 3, 2021.Â
GE Healthcare Acquiring Zionexa for Access to Breast Cancer PET Imaging Agent
GE intends to scale access to the PET imaging agent so at least 75 percent of metastatic breast cancer patients in the US have access to it by 2023.
Fusion Pharmaceuticals, Merck to Study Targeted Radiation, Keytruda Combo in Certain Solid Cancers
The companies will conduct a Phase I/II clinical trial to evaluate Fusion's FPI-1434 and Merck's checkpoint inhibitor in solid tumors expressing IGF-1R.
SpringWorks Therapeutics Licenses TEAD Inhibitor Portfolio From Belgian Research Institutes
The deal is worth $296 million, with SpringWorks paying $11 million upfront and up to $285 million upon reaching certain milestones.